|Dr Raleigh invents the immunochemical, 2-nitroimidazole hypoxia marker technique. A patent is applied for.
|Dr. Raleigh in collaboration with Drs. Donald Thrall and Mark Cline at the College of Veterinary Medicine at North Carolina State University publish the first use of an immunochemical, 2-nitroimidazole hypoxia marker in the clinical setting of a veterinary hospital.
|The first patent for immunochemical nitroimidazole hypoxia markers is issued.
|The US FDA clears intravenous pimonidazole HCl as an Investigational New Drug for clinical studies of tissue hypoxia.
|The Hypoxyprobe Division of Natural Pharmacia International, Inc. prepares pimonidazole HCl on a large scale for preclinical and clinical studies.
|The first cancer patient receives pimonidazole HCl as an immunochemical hypoxia marker in May 1995 in the Department of Radiation Oncology at UNC Chapel Hill.
|Arteel et al. publish the first use of pimonidazole HCl as immunochemical hypoxia marker in animal tissue.
|Kennedy et al. publish the first report of the clinical use of pimonidazole HCl as an immunochemical hypoxia marker.
|The Hypoxyprobe trademark is published.
|A second patent for Hypoxyprobe products is issued.
|The first European report of the clinical use of pimonidazole HCl as an immunochemical hypoxia marker is published.
|Natural Pharmacia International, Inc. awards a five-year exclusive license to Chemicon, International for the marketing of Hypoxyprobe products for preclinical studies.
|Dr. Raleigh is appointed Vice President, Research and Development with special responsibility for the Hypoxyprobe Division at Natural Pharmacia International.
|The FDA clears orally administered pimonidazole HCl as an Investigational New Drug for clinical studies of tissue hypoxia.
|Kleiter et al. publish the first report of orally administered pimonidazole HCl in dogs in the clinical setting of a Veterinary Hospital at North Carolina State University under the supervision of Donald E. Thrall, DVM, PhD.
|Natural Pharmacia International, Inc. ends the exclusive marketing license with Chemicon International. Hypoxyprobe, Inc. is created to market an expanded line of Hypoxyprobe products. An online Hypoxyprobe Store is opened.
|Threshold Pharmaceuticals adopts pimonidazole HCl as an immunochemical hypoxia marker in multicenter clinical studies of their hypoxia-activated prodrug, TH302.
|The first report of the clinical use of orally administered pimonidazole HCl.
|Proacta, Inc. adopts pimonidazole as a hypoxia marker to complement clinical studies of their hypoxia-activated prodrug, PR104.
|A third patent is issued for Hypoxyprobe products with a focus on therapeutics based on hypoxia-seeking pimonidazole as lead compound.
|Oral pimonidazole HCl is used in clinics in the USA, Canada and Norway.
|Hypoxyprobe trademark is renewed.
|The total number of publications that report the use of pimonidazole as an immunochemical hypoxia marker reaches 549. 70 of the publications are based on clinical studies.
|Hypoxyprobe, Inc. develops non-invasive versions of Hypoxyprobe products for the detection of tissue hypoxia (positron emission tomography, near infrared spectroscopy and magnetic resonance spectroscopy) and therapeutics based on the hypoxia seeking properties of the lead compound, pimonidazole.